Express Pharma
Home  »  Latest Updates  »  Lupin gets 3 observations from USFDA for Aurangabad plant

Lupin gets 3 observations from USFDA for Aurangabad plant

21

The USFDA carried out the inspection at the plant from May 6 to May 15

Drug maker Lupin on May 15 said it has received three observations from the US health regulator for its Aurangabad-based manufacturing facility.
The US Food and Drug Administration (USFDA) carried out the inspection at the plant from May 6 to May 15, Lupin said in a statement.

“The inspection at the Aurangabad facility closed with three observations. The company is confident of addressing them satisfactorily,” it added.

Shares of Lupin on May 15 ended 3.22 percent lower at Rs 783.10 apiece on the BSE.

Comments are closed.